Key Takeaways

  1. Germany’s health data access splits into two distinct routes: statutory access through FDZ Gesundheit and commercial licensing through research institutes and data vendors
  2. FDZ Gesundheit covers roughly 75 million statutory health insurance members, offering the strongest population representativeness but an application timeline measured in months
  3. Commercial providers like InGef, IQVIA Germany, and INSIGHT Health typically cover 8 to 15 million insured persons but deliver much faster access for time-sensitive research
  4. The Gesundheitsdatennutzungsgesetz, enacted in March 2024, centralized statutory data access but did not create a fast-track commercial licensing option
  5. Choosing the right route depends on whether a research question prioritizes nationwide coverage and regulatory credibility or speed and flexible study design

Germany holds one of Europe’s richest health data environments, but reaching that data takes more than knowing it exists. Pharmaceutical market access and HEOR teams researching German patient populations quickly find that the country’s data infrastructure splits into separate, differently governed pathways, each with its own rules about who can apply, how long approval takes, and how much of the population the resulting evidence actually represents. Getting this wrong can mean months of wasted planning or evidence that regulators view skeptically.

Germany’s 75-Million-Patient Data Puzzle

Roughly 90% of Germany’s population is enrolled in the statutory health insurance system, known as the Gesetzliche Krankenversicherung or GKV. That coverage produces longitudinal claims records spanning ambulatory diagnoses, hospital treatment, prescription histories, and procedure coding across approximately 75 million insured people. For research teams working on pharmacoepidemiological studies, market access dossiers, or real-world evidence generation, that scale is rare among European health data sources.

The data does not sit in one accessible repository. It is distributed across statutory insurers, research institutes, and commercial vendors, each operating under different legal frameworks and offering different slices of the population.

Choosing a data source in Germany means first understanding that the question is not simply which database is biggest. It is which access route actually fits the research question, the required timeline, and the level of regulatory scrutiny the resulting evidence needs to withstand.

Two Access Models, Not One

Before comparing individual data providers, it helps to understand that German health data access runs on two fundamentally different tracks. Confusing them is a common early misstep among teams approaching this market for the first time.

Statutory Access via FDZ Gesundheit

The Forschungsdatenzentrum Gesundheit, housed within the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), is the central access point for pseudonymized statutory health insurance data. Access works through a formal, application-based process: organizations submit a research proposal, that proposal is evaluated against eligibility criteria, and approved applicants work within a secure analysis environment rather than receiving a raw data export. This route offers the broadest population coverage available in Germany along with the strongest regulatory standing, but the tradeoff is a review and approval timeline measured in months.

Commercial Licensing via Research Institutes and Vendors

Alongside the statutory route, organizations including InGef, INSIGHT Health, and IQVIA Germany offer German health data through commercial licensing arrangements. These datasets are built from claims data that participating health insurance funds contribute voluntarily, anonymized to GDPR standards, and made available under contractual terms that skip the formal statutory application process entirely. Coverage runs narrower, typically between 8 and 15 million insured persons rather than the full statutory population, but the payoff is faster access and a licensing structure that feels more familiar to pharma procurement teams accustomed to vendor contracts.

Neither model wins outright. The right choice depends on the research question itself, the population coverage it demands, the regulatory weight the evidence needs to carry, and how much runway the project has.

How the GDNG Rewrote the Rules in 2024

The Gesundheitsdatennutzungsgesetz, or GDNG, was enacted in March 2024, marking a significant shift in German health data governance. Before this law, health data research typically relied on bilateral arrangements negotiated separately with individual health insurance funds, a fragmented process that often produced datasets skewed toward specific regions or demographic groups rather than reflecting the country as a whole.

The GDNG replaced that patchwork with a centralized legal framework, making pseudonymized SHI data accessible for approved research and public interest purposes through FDZ Gesundheit. This matters for research credibility, since a centralized, population-representative dataset carries different weight in a regulatory submission than a collection of regional insurer agreements ever could.

The GDNG did not create a fast-track commercial licensing option, and the FDZ Gesundheit application process remains a formal regulatory procedure with review timelines still measured in months. It also did not eliminate the commercial routes through InGef, INSIGHT Health, or IQVIA for projects where speed matters more than nationwide representativeness. Teams still need a well-designed research protocol before applying, since submissions that fail to clearly articulate the research question, methodology, and data minimization approach simply are not approved.

FDZ Gesundheit: Coverage vs. Timeline Tradeoffs

FDZ Gesundheit provides access to pseudonymized SHI data covering ambulatory diagnoses coded in ICD-10, hospital admissions and DRG codes, ambulatory procedures under EBM classification, and prescription data using ATC codes, alongside sociodemographic variables. A future data model iteration is expected to incorporate information from the elektronische Patientenakte, Germany’s electronic patient record system, once that system holds enough populated data to be useful for research.

Who Can Apply and for What Purpose

Eligibility is not open-ended. Applicant institutions must be registered and located within the EU or EEA, and the proposed research question must correspond to one of the purposes the GDNG legally permits. Because the research environment is designed to serve the public interest, purely commercial or product-development-oriented research questions do not automatically qualify. This distinction matters directly for pharmaceutical teams considering the FDZ route for market research or product positioning work, since those purposes generally fall outside the permitted scope described in the FDZ access framework.

Data Economy Rules, Output Limits, and Costs

FDZ Gesundheit operates under a principle of data economy, meaning each approved application receives only the minimum data judged necessary for that specific research question. That has a practical consequence worth planning around: if a research team discovers mid-project that it needs additional variables, the dataset generally cannot simply be expanded, and a new or modified application may be required instead.

Several other operational constraints shape how a project unfolds inside the FDZ environment:

  1. Analysis happens within a secure server-based environment using prescribed software, with R, Python, or SQL available for analytical work.
  2. Result outputs are capped at five tables and a maximum of 2,400 data cells, with every result subject to review before release.
  3. Access operates within fixed time windows, so project timelines need to be planned around the granted access period rather than adjusted freely afterward.
  4. Costs include a basic fee plus charges tied to reporting years, analysis environments, and usage days, alongside optional services; reduced fees exist for accredited universities and public research institutions but do not extend to the pharmaceutical industry.

No standard price quote is issued in advance, so applicants need to estimate costs based on their planned use of the research environment before committing to the process.

Commercial Providers: Speed Over Scale

For teams that need results on a shorter timeline, or whose research question does not require nationwide representativeness, commercial data providers offer a practical alternative to the statutory route.

InGef’s Research Partnership and DARWIN EU Standing

InGef, the Institut für angewandte Gesundheitsforschung Berlin, operates its research database across approximately 8.8 million insured persons spanning 52 statutory health insurance funds. Rather than simply licensing raw data, InGef typically functions as a research partner, designing and conducting studies on behalf of client organizations using anonymized claims data covering sociodemographic information, drug prescriptions, and outpatient and inpatient treatment histories linked longitudinally over six consecutive calendar years.

InGef’s anonymization methodology has been published and peer-reviewed, giving it a documented compliance basis under GDPR Article 4(1) standards that many commercial providers cannot match. InGef is also listed as a data partner in the European DARWIN EU network, the EMA’s real-world evidence network, a meaningful signal of methodological credibility for teams whose evidence needs to hold up in regulatory contexts across multiple countries.

IQVIA and INSIGHT Health’s Panel-Based Products

IQVIA Germany and INSIGHT Health take a different approach, built around panel-based data products rather than a single unified claims database.

  1. IQVIA Germany’s Longitudinal Prescription Database (LRx) tracks individual patient prescriptions over time through a sample of German pharmacies, useful for treatment pattern analysis and therapy switching research, though its panel design means it is not population-representative in the way statutory or research-institute claims data can be.
  2. IQVIA’s Disease Analyzer provides GP panel-based electronic medical record data covering diagnoses, prescriptions, and referrals, offering a window into primary care treatment pathways.
  3. INSIGHT Health’s core product is longitudinal prescription data drawn from pharmacy point-of-sale records, covering approximately 80% of the German pharmacy market and providing strong visibility into what is being prescribed and where.

These panel-based products excel at commercial analytics, competitive intelligence, and prescription monitoring. They serve epidemiological or HEOR research less well when that research depends on linked patient-level diagnoses and outcomes, since prescription volume data alone cannot show which patients received which treatment or what happened to them afterward.

Population Coverage Determines Regulatory Credibility

The thread running through every one of these access routes is the relationship between population coverage and regulatory acceptance. Data drawn from a nationally representative population, like the roughly 75 million GKV-insured persons accessible through FDZ Gesundheit, carries a documented governance trail that regulators and health technology assessment bodies tend to weigh heavily. Data from a narrower panel or a regional commercial dataset can still answer many research questions well, but it usually needs more careful characterization in a study protocol to address representativeness concerns before a submission moves forward.

This is exactly why the research question needs to come first, before any provider is selected. A study on a rare disease with a small patient population may genuinely need the scale that only a nationwide dataset can offer, since a smaller commercial panel might not contain enough affected patients to produce statistically meaningful results. A commercial analytics project tracking prescribing trends for a recently launched product, on the other hand, may find that a faster commercial license delivers exactly what is needed without the months-long wait tied to a statutory application.

Matching the access route to the actual research need, rather than to provider familiarity or past habit, separates evidence that holds up under regulatory scrutiny from evidence that raises more questions than it answers. For teams weighing these tradeoffs on an upcoming project, understanding German health data access routes in advance can save months of avoidable rework later.

MEDDDICAL

Aptos 221
Edificio D2C
Sotogrande
Cadiz
11310
Spain

About The Author
NewsNetwork